Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 357,011 | 120,256 | 109,966 | 68,395 | 47,976 |
| Marketable Securities | 491,265 | 368,488 | 264,915 | 338,771 | 394,442 |
| Receivables | N/A | N/A | 15,000 | N/A | N/A |
| Other current assets | 0 | 0 | 3,762 | 2,537 | 135 |
| TOTAL | $871,214 | $510,268 | $405,317 | $419,416 | $451,273 |
| Non-Current Assets | |||||
| PPE Net | 43,175 | 50,457 | 48,134 | 13,334 | 11,881 |
| Investments And Advances | 771,158 | 362,159 | 61,434 | 152,328 | 125,187 |
| Other Non-Current Assets | 57,265 | 55,151 | 60,874 | 18,056 | 17,564 |
| TOTAL | $871,598 | $467,767 | $170,442 | $183,718 | $154,632 |
| Total Assets | $1,742,812 | $978,035 | $575,759 | $603,134 | $605,905 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,015 | 5,989 | 7,075 | 4,335 | 4,005 |
| Accrued Expenses | 42,274 | 34,867 | 33,864 | 27,502 | 22,971 |
| Other current liabilities | 242 | 223 | 524 | 303 | 228 |
| TOTAL | $83,212 | $67,767 | $85,691 | $71,343 | $92,542 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 22,925 | 13,576 | 37,883 | 35,260 | 61,739 |
| Other Non-Current Liabilities | 67,034 | 72,423 | 77,028 | 12,394 | 13,290 |
| TOTAL | $79,936 | $74,649 | $95,097 | $41,640 | $53,725 |
| Total Liabilities | $163,148 | $142,416 | $180,788 | $112,983 | $146,267 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 81,642 | 64,944 | 61,112 | 55,184 | 51,704 |
| Common Shares | 8 | 7 | 6 | 6 | 5 |
| Retained earnings | -1,065,961 | -754,610 | -530,752 | -383,790 | -228,982 |
| Other shareholders' equity | 1,800 | -1,485 | -552 | -4,949 | -660 |
| TOTAL | $1,579,664 | $835,619 | $394,971 | $490,151 | $459,638 |
| Total Liabilities And Equity | $1,742,812 | $978,035 | $575,759 | $603,134 | $605,905 |